Tricida, Inc. (TCDA): Price and Financial Metrics
GET POWR RATINGS... FREE!
TCDA Stock Price Chart Interactive Chart >
TCDA Price/Volume Stats
| Current price | $0.22 | 52-week high | $13.85 |
| Prev. close | $0.23 | 52-week low | $0.19 |
| Day low | $0.21 | Volume | 4,580,100 |
| Day high | $0.24 | Avg. volume | 3,134,446 |
| 50-day MA | $4.49 | Dividend yield | N/A |
| 200-day MA | $8.54 | Market Cap | 12.18M |
Tricida, Inc. (TCDA) Company Bio
Tricida, Inc., a late-stage pharmaceutical company, focuses on developing therapeutics to address renal, metabolic, and cardiovascular disease. Its lead product candidate, TRC101, a non-absorbed orally-administered polymer drug that is in Phase III clinical trials used to treat metabolic acidosis in patients with chronic kidney disease. The company was founded in 2013 and is based in South San Francisco, California.
Latest TCDA News From Around the Web
Below are the latest news stories about TRICIDA INC that investors may wish to consider to help them evaluate TCDA as an investment opportunity.
15 Most Shorted Stocks Right NowIn this article, we discuss the 15 most shorted stocks right now. If you want to read about some more shorted stocks, go directly to 5 Most Shorted Stocks Right Now. The stock market has been volatile in the past few months as soaring inflation and rising rates combine to create an uncertain business environment […] |
Peninsula drug company Tricida cutting more than half of staff after clinical trial failureThe company earlier this month said it was looking at "strategic alternatives," including a sale in whole or in part. |
Needham Sticks to Its Hold Rating for Tricida (TCDA)In a report released today, Serge Belanger from Needham maintained a Hold rating on Tricida (TCDA - Research Report). The company's shares closed yesterday at $0.27.According to TipRanks, Belanger is an analyst with an average return of -4.8% and a 40.40% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Pacira Pharmaceuticals, Revance Therapeutics, and KalVista Pharmaceuticals.The analyst consensus on Tricida is currently a Moderate Sell rating.See today’s best-performing stocks on TipRanks >>Based on Tricida's latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $28.54 million. |
Tricida Announces Third Quarter 2022 Financial ResultsSOUTH SAN FRANCISCO, Calif., November 14, 2022--Tricida, Inc. (Nasdaq: TCDA) announced today financial results for the three and nine months ended September 30, 2022 and provided an update on key initiatives. |
Peninsula kidney drug company weighs 'strategic alternatives' after clinical trial flopThe nine-year-old company, which once employed 200 people but now has less than 60, is the third in a triumvirate of kidney drug ventures started by a team led by Gerrit Klaerner. |
TCDA Price Returns
| 1-mo | -22.86% |
| 3-mo | -98.13% |
| 6-mo | -97.56% |
| 1-year | -97.20% |
| 3-year | -99.48% |
| 5-year | N/A |
| YTD | -97.70% |
| 2021 | 35.60% |
| 2020 | -81.32% |
| 2019 | 60.05% |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...